Novo Nordisk to Cut Prices on Popular Drugs
Novo Nordisk has revealed plans to reduce the list prices of its well-known diabetes and weight loss medications, Ozempic and Wegovy, by as much as 50% starting next year in the U.S. market.
The Danish pharmaceutical firm announced that these price cuts will be effective from January 1, 2027, aligning with the rollout of new, lower costs for the same medications under Medicare for seniors.
According to the company, the list prices for various doses of Ozempic and Wegovy will drop to $675, which reflects a 50% decrease for Wegovy and a 35% reduction for Ozempic as compared to current prices. This adjustment will also extend to Rybelsus tablets.
Jamie Miller, who is the executive vice president of U.S. operations, stated, “This move to reduce the list price of Wegovy and Ozempic is the best way to seize an unprecedented opportunity to assist over 100 million people dealing with obesity and 35 million individuals with type 2 diabetes in the U.S.”
“Today’s actions respond to significant demand, help eliminate cost barriers, and ultimately allow more patients to benefit from Wegovy and Ozempic,” he noted.
Miller further emphasized that these price reductions aim to make their innovative treatments accessible to a broader audience, particularly those affected by high out-of-pocket costs linked to list prices, which can impact individuals enrolled in high-deductible health plans or those with coinsurance designs.
Novo Nordisk’s GLP-1 drug features semaglutide as the active ingredient and has received FDA approval for use in treating obesity. Similarly, Ozempic is FDA-approved for managing type 2 diabetes.
This pricing change won’t alter direct patient costs or out-of-pocket expenses. As competition in the GLP-1 market intensifies, Novo Nordisk’s pricing strategies are becoming increasingly consumer-driven, with the company currently offering Wegovy on its direct-to-consumer website for $349, roughly one-third of its list price.
Both Novo Nordisk and its competitor, Eli Lilly, have previously reduced prices amid negotiations with the U.S. government to enhance product accessibility. They now face competition from lower-cost medication combinations offered through telemedicine platforms.
